Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

VOLUNTARY ANNOUNCEMENT

APPLICATION FOR CLINICAL TRIAL OF ANTI-TIGIT FC FUSION PROTEIN HLX53 FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OR LYMPHOMAS WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

A. INTRODUCTION

This announcement is made by Shanghai Henlius Biotech, Inc. (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Company.

The board of directors of the Company (the "**Board**") is pleased to announce that, recently, application for phase 1 clinical trial of anti-TIGIT Fc fusion protein HLX53 ("**HLX53**") independently developed by the Company for the treatment of advanced solid tumours or lymphomas was approved by the National Medical Products Administration (the "**NMPA**"). The Company is proposing to commence the phase 1 clinical trial in mainland China (excluding Hong Kong, Macau and Taiwan regions) when clinical trial conditions are fulfilled.

B. INFORMATION ABOUT HLX53

HLX53 is an innovative anti T cell immunoreceptor with immunoglobulin and ITIM domains ("**TIGIT**") Fc fusion protein independently developed by the Company, consisting of variable domain of heavy chain of heavy-chain antibody (VHH) and wildtype IgG1 Fc, which is intended to be used for the treatment of advanced solid tumours or lymphomas. TIGIT is an inhibitory receptor, which is mainly expressed on natural killer ("**NK**") cells, activated CD8+ T and CD4+ T cells, and T regulatory cells (Treg). TIGIT binds to the ligand CD155 (also called Poliovirus receptor, "**PVR**") mainly expressed on antigen-presenting cells (APC) or the surface of tumour cells, thereby downregulating cell functions of T cells and NK cells. Studies have shown that HLX53 can specifically bind to human TIGIT and block the binding of TIGIT/PVR to cut off the downstream negative signals and reactivate the effect of immune response to tumours of T cells.

C. MARKET CONDITION

As of the date of this announcement, no anti-TIGIT drug has been approved for marketing globally.

WARNING STATEMENT WITH REFERENCE TO THE REQUIREMENTS UNDER RULE 18A.05 OF THE RULES GOVERNING THE LISTING OF SECURITIES ON THE STOCK EXCHANGE OF HONG KONG LIMITED: The Company cannot guarantee the successful development and commercialization of HLX53. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 30 June 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr.Yifang Wu, Ms. Xiaohui Guan, Dr. Aimin Hui and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.